相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Validity of chemotherapy information derived from routinely collected healthcare data: A national cohort study of colon cancer patients
Jemma M. Boyle et al.
CANCER EPIDEMIOLOGY (2021)
Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors
Emre Yekeduz et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
Cynthia Huang Bartlett et al.
PLOS ONE (2020)
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
A. Sobrero et al.
ANNALS OF ONCOLOGY (2018)
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
A. Grothey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Can Chemotherapy-Related Acute Care Visits Be Accurately Identified in Administrative Data?
Monika K. Krzyzanowska et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Data Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC)
Annie Herbert et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2017)
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial
A. Passardi et al.
ANNALS OF ONCOLOGY (2015)
Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data
Jeanne S. Mandelblatt et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
Population-Based Assessment of Emergency Room Visits and Hospitalizations Among Women Receiving Adjuvant Chemotherapy for Early Breast Cancer
Katherine Enright et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials
A. J. Templeton et al.
ANNALS OF ONCOLOGY (2013)
Adjuvant Chemotherapy and Risk of Gastrointestinal, Hematologic, and Cardiac Toxicities in Elderly Patients With Stage III Colon Cancer
Chung-Yuan Hu et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2012)
Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer A Population-Based Analysis
Hanna K. Sanoff et al.
CANCER (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Systematic review of discharge coding accuracy
E. M. Burns et al.
JOURNAL OF PUBLIC HEALTH (2012)
Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
John H. Strickler et al.
ONCOLOGIST (2012)
Multiple imputation using chained equations: Issues and guidance for practice
Ian R. White et al.
STATISTICS IN MEDICINE (2011)
Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score
J. N. Armitage et al.
BRITISH JOURNAL OF SURGERY (2010)
Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer
Katherine L. Kahn et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
M. L. Rothenberg et al.
ANNALS OF ONCOLOGY (2008)
Raltitrexed (Tomudex®) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)
Ivan Popov et al.
EUROPEAN JOURNAL OF CANCER (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F. Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Measuring clinically significant chemotherapy-related toxicities using medicare claims from cancer and leukemia group B (CALGB) trial participants
Elizabeth B. Lamont et al.
MEDICAL CARE (2008)
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group
Rainer Porschen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07
J. Philip Kuebler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Beyond randomized controlled trials: A critical comparison of trials with nonrandomized studies
Henrik Toft Sorensen et al.
HEPATOLOGY (2006)
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer
Michael J. Hassett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Capecitabine as adjuvant treatment for stage III colon cancer
C Twelves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The impact of socioeconomic status and race on trial participation for older women with breast cancer
CP Gross et al.
CANCER (2005)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30
EK Fromme et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort
JZ Ayanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer
XLL Du et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Capecitabine (Xeloda®) in combination with oxaliplatin:: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
E Díaz-Rubio et al.
ANNALS OF ONCOLOGY (2002)
Completeness of safety reporting in randomized trials - An evaluation of 7 medical areas
JPA Ioannidis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
分享论文
